Primary lymphoid tumors of orbit are rare. Sometimes they pose difficulty in differentiating malignant non-odgkin's lymphoma of the orbit from benign lymphoid hyperplasia or pseudotumor of the orbit by growth characteristics and histologic examination of a biopsy specimen. Consequently, systemic work-p for staging of the disease before the initiation of treatment is essential. All lymphoid tumors of the orbit are radiosensitive and the response to radiotherapy is rapid and complete. Radiation dose for permanent control varies from 2,400 to 4,500rads in 2.5~4 weeks depending on extent and location of the disease. A case of localized lymphoma of the orbit was treated with radiotherapy. For the following 15 months, the patient was clinically free of disease without any evidence of side effects of radiation treatment.
Biopsy ; Humans ; Hyperplasia ; Lymphoma ; Orbit* ; Radiotherapy

No abstract available.
Hodgkin Disease* ; Lymphoma, Non-Hodgkin* ; Radiotherapy*

Malignant lymphoma of the sinus is very rare but potentially radiocurable neoplasm. The disease is tend to be localized to the sinus and spread to adjacent local structure on initial presentation, and change to generalized lymphoma is uncommon. Most of sinus lymphoma is diffuse histiocytic type. Radiotherapy to the primary and neck nodes is the treatment of choice, and a survival rate of 50~70% can be expected.
Lymphoma* ; Maxillary Sinus* ; Neck ; Radiotherapy ; Survival Rate

Malignant lymphoma is mainly found in lymphnodes but extralymphatic organs may be rarely involved. Malignant lymphoma of the orbit is relatively rare representing less than 1% of all non-Hodgkin's lymphoma. All lymphoid tumors of the orbit are radiosensitive and are mainly treated wiht curative intent by irradiation. We report a case of orbital malignant lymphoma in a 41-year-old male patient. He received radiation therapy and subsequent enucleation and till now is clinically free of the disease.
Adult ; Humans ; Lymphoma* ; Lymphoma, Non-Hodgkin ; Male ; Orbit* ; Radiotherapy*

In order to evaluate the role of radiation therapy in the management of low-grade mucosa-associated lymphoid tissue lymphoma of the stomach (MLS), in patients with no evidence of Helicobacter pylori (H. pylori) or who had not responded to H. pylori eradication treatment, we analyzed the treatment outcome of patients who had received radiotherapy alone. Between Jan 1995 and May 2001, 6 patients with low- grade MLS were treated with radiotherapy alone. The median radiation dose was 30.6 Gy (range; 30 - 39 Gy) in a daily fractions of 1.5 - 1.8 Gy. Each patient had an endoscopic esophago-gastro-duodenoscopy with biopsy, 4 weeks after the completion of radiotherapy and every 6 months thereafter. A complete response was obtained in all patients. All patients were followed-up without evidence of disease, and no patient suffered a relapse. There was neither perforation nor hemorrhage of the stomach in any of the patients. No renal or hepatic toxicity were noted, and no secondary malignancies developed. In conclusion, radiotherapy should be considered as the preferred treatment method for low-grade MLS, in patients with no evidence of H. pylori infection, or who do not respond to antibiotic therapy, due to the significant benefits in gastric preservation and low morbidity.
Adult ; Aged ; Female ; Human ; Lymphoma, Low-Grade/*radiotherapy ; Lymphoma, Mucosa-Associated Lymphoid Tissue/*radiotherapy ; Male ; Middle Age ; Radiotherapy/adverse effects ; Stomach Neoplasms/*radiotherapy

The purpose of this study was to aid in the prediction of tumor cell tolerance to radiotherapy and/or chomotherapy . For this study, cell surviving curves were obtained for mouse lymphoma YAC-1 cell line using semiautomated MTT assay. 2, 4, 6, 8, 10Gy were irradiated at a dose rate of 210cGy/min using 60Co Irradiator ALDORADO 8. After irra diation, YAC-1 cell lines(3X10(4) cells/ml) were exposed to bleomycin or cisplatin for 1 hour. The viable cells were determined for each radiation dose and/or each concentration of drug at the 4th day. And they w ere compared to control values. The obtained results were as follows: 1. The surviving curve with gentle slope was obtained after irradiation of 2, 4, 6, 8, 10Gy on YAC-1 cell line. 2. The cytotoxicity of bleomycin or cisplatin was increased significantly at all concentration of 0.2microgram/ml, microgram/ml an d 20microgram/ml on YAC-1 cell line (P<0.01). 3. There were no significant differences of surviving fractions among 4Gy, 6Gy, and 8Gy after irradiation of each radia tion dose with 2microgram/ml of bleomycin compared with irradiation only on YAC-1 cell line(P<0.05). 5. There were significant differences of surviving fractions between the groups of irradiation only and the groups of i rradiation with 2microgram/ml of bleomycin or cisplatin at all doses of 2, 4, 6, 8 and 10Gy on YAC-1 cell line(P<0.05).
Animals ; Bleomycin ; Cell Line* ; Cisplatin ; Lymphoma ; Mice ; Radiation Tolerance* ; Radiotherapy

Among 238 patients Non-odgkin's lymphoma received radiotherapy at Yonsei Cancer center, Yonsei University Medical College, from 1970 to 1981, 30 patients presented with localized(Stage I & II) gastrointestinal lymphomas. Retrospective analysis of these 30 cases in an attempt to evaluate the influence of various prognostic factors and the effectiveness of therapy is presented. Overall 5 year survival rate of 30 cases of primary gastrointestinal lymphoma was 48%. Bulk of residual disease after initial surgery and stage were significant prognostic factors. Stage I with small residual disease treated with post-p irradiation achieved 100% 5 year survival rate. So above group is considered curable with surgery and post-p irradiation. 80% of Stage II with small residual disease showed 31.5% 5 year survival rate. Non of them died with local failure. So, we suggest that complete surgical resection of tumor mass should be attempted initially in the management of localized gastrointestinal lymphomas and systemic chemotherapy is needed in addition to post-p irradiation in the cases of Stage II and large residual disease after initial surgery.
Drug Therapy ; Humans ; Lymphoma* ; Radiotherapy ; Retrospective Studies ; Survival Rate

No abstract available.
Drug Therapy, Combination* ; Larynx* ; Lymphoma, Non-Hodgkin* ; Radiotherapy*

Primary cutaneous plasmacytoma (PCP) is a very rare cutaneous B-cell lymphoma that arises primarily in the skin. A few cases of PCP have been reported previously. PCPs are histologically similar to cutaneous B-cell lymphoma and are characterized by dense monoclonal plasma cell infiltration in the dermis. PCP can manifest as a single lesion or as multiple lesions. A solitary lesion can be treated with surgical excision or local radiotherapy. We describe the case of a patient with primary cutaneous plasmacytoma that was treated with intralesional steroid injections.
Dermis ; Humans ; Lymphoma, B-Cell ; Plasma Cells ; Plasmacytoma* ; Radiotherapy ; Skin

Objective To describe a rare case of acute lymphocytic leukemia (ALL) with optic nerve head tumor cell infiltration treated with external beam irradiation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma ; Optic Nerve ; Radiotherapy